June 25, 2018 PR-M06-18-NI-081
STAINES-UPON-THAMES, United Kingdom /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced creation of a Scientific Advisory Council (SAC) designed to provide external scientific guidance related to its strategy, research and development plans, and medical programs. Steven Romano, MD, Executive Vice President and Chief Scientific Officer, chaired today's inaugural meeting and expects the Council to contribute insights and external perspective to Mallinckrodt's Science and Technology organization, as well as serving as independent scientific advisors to MNK's Executive Committee and Board of Directors.
Joining Dr. Romano as charter members of the SAC are three leading experts in their respective fields, selected, in part, because of their experience and expertise in areas that are central to Mallinckrodt's current portfolio – namely, regenerative medicine, neonatal critical care and autoimmune and rare diseases. The first three external members include:
"Mallinckrodt's Scientific Advisory Council reflects our ongoing commitment to being a premier, innovation-driven scientific organization, focused on developing pharmaceutical therapies that can improve outcomes for patients with severe and critical conditions," said Dr. Romano. "We are very pleased these exceptional physician scientists have agreed to join our SAC and we plan to add more members over time. Today's inaugural meeting was highly productive, and we look forward to ongoing collaboration with these experts."
CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Investor Relations and Strategy Officer
314-654-3638
daniel.speciale@mnk.com
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mnk.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mnk.com
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products.